Technical Reports | June 2022

EGPAF Pediatric Strategy 2022-2024

Overview

In 2020, 1.7 million children (0-14 years) were living with HIV globally, representing 4.5% of the 37.7 million individuals living with HIV. Between 2016 and 2020, pediatric antiretroviral therapy (ART) coverage increased from 44% to 54%; however, during this time, adult ART coverage increased from 55% to 74%, highlighting the persistent discrepancy between pediatric and adult treatment.

The global pediatric focus has not been matched with requisite resourcing from donors and ministries of health. Approximately 6% to 7% of the fiscal year (FY) 2020 U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) funding was for dedicated pediatric services, and pediatric-focused funding from private donors is decreasing. At the national level, pediatric HIV continues to struggle for funding, political focus, and prioritization.

EGPAF’s role as a leading advocate, innovator, researcher, and implementer in the pediatric HIV space is integral to maintaining high prioritization.

To do this, EGPAF needs to continue to demonstrate programmatic leadership across its pediatric HIV portfolio, generate evidence in areas of emerging importance, and maintain a core institutional focus on pediatric HIV. Through this strategy, EGPAF seeks to solidify our leadership in the pediatric HIV response in coming years, working toward addressing critical gaps in HIV services with tactical partnerships while innovating for the most cost-effective, sustainable pediatric HIV strategies for the future.

Created by:

Elizabeth Glaser Pediatric AIDS Foundation

Country:

Global